Core Insights - AnaptysBio, Inc. has released updated data from the Phase 2b trial of rosnilimab, demonstrating significant efficacy in treating rheumatoid arthritis [1][2] - The drug showed durable responses and was well tolerated compared to standard biologics and JAK inhibitors [2][4] - Analyst Emily Bodnar upgraded AnaptysBio's rating from Neutral to Buy, raising the price target from $22 to $38 based on positive trial data [4] Efficacy and Safety - In a 424-patient trial, rosnilimab achieved JAK-like efficacy on multiple measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI) [1] - At Week 12, all three doses of rosnilimab (100mg Q4W, 400mg Q4W, 600mg Q2W) showed statistically significant reductions in DAS-28 CRP and ACR20 compared to placebo [2] - By Week 12, 45% of patients achieved CDAI LDA, increasing to 69% by Week 14 across all doses [2] Patient Outcomes - Rosnilimab demonstrated clinically meaningful improvements in patient-reported outcomes, including pain visual analog scale (VAS) and HAQ-Disability Index [4] - As of the March 11, 2025 data cutoff, 83% of patients remained in LDA at Week 34, with a median CDAI of 13 for those not sustaining LDA [3] Competitive Landscape - Data from the SELECT-CHOICE trial indicated similar efficacy results for AbbVie’s Rinvoq and Bristol Myers Squibb’s Orencia, aligning with rosnilimab's outcomes [5] - In contrast, Eli Lilly's discontinued PD-1 agonist peresolimab showed a decline in CDAI LDA rates, highlighting rosnilimab's stronger performance [6] - Johnson & Johnson is expected to present early data for its PD-1 agonist at the upcoming EULAR conference, although its study is smaller than AnaptysBio's [6]

Core Insights - AnaptysBio's investigational drug rosnilimab shows a best-in-disease profile for treating moderate-to-severe rheumatoid arthritis (RA), demonstrating JAK-like efficacy and durable responses [1][2][3] Efficacy and Clinical Outcomes - In a Phase 2b trial with 424 patients, rosnilimab achieved significant clinical improvements, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI) [1][2][3] - By Week 12, 45% of patients achieved CDAI LDA, increasing to 69% by Week 14, indicating a strong response to treatment [3][4] - Rosnilimab demonstrated a rapid onset of ACR20 response, comparable to upadacitinib, with a substantial decrease in C-reactive protein (CRP) levels [2][3] Safety and Tolerability - Rosnilimab exhibited a favorable safety profile, with no treatment-related serious adverse events (SAEs) reported and a low incidence of injection site reactions [10][11] - Less than 2% of patients discontinued treatment due to adverse events, indicating good tolerability [10][11] Market Potential - The findings suggest rosnilimab could capture a significant share of the ~$20 billion U.S. RA market, with potential for extended dosing intervals [2][3] - The company aims to complete ongoing studies for rosnilimab in ulcerative colitis, with initial data expected in Q4 2025 [2][14] Mechanism of Action - Rosnilimab targets PD-1+ T cells, aiming to restore immune homeostasis and reduce inflammation associated with RA [19][21] - The drug demonstrated a ~90% reduction in PD-1 T cells and a ~50% reduction in PD-1+ T cells, indicating robust pharmacological activity [8][19] Future Developments - AnaptysBio plans to advance rosnilimab's clinical development and explore its application in other autoimmune diseases [21][22] - The company is committed to developing innovative treatments that address the long-term needs of patients with chronic inflammatory conditions [21][22]

Core Insights - AnaptysBio reported strong Phase 2b efficacy data for its lead program, rosnilimab, in rheumatoid arthritis, with plans to present updated data in June 2025 and initial ulcerative colitis data in Q4 2025 [2][7][8] - The company is advancing its autoimmune portfolio with multiple catalysts expected in the coming years, including ongoing Phase 1 trials for ANB033 and ANB101 [2][4][5] - AnaptysBio remains well-capitalized with a cash runway extending through the end of 2027, supported by a $75 million stock repurchase program and anticipated royalties from collaborations [2][11][12] Financial Updates - For Q1 2025, AnaptysBio reported collaboration revenue of $27.8 million, a significant increase from $7.2 million in Q1 2024, driven by royalties from Jemperli and revenue from the Vanda license agreement [11][19] - Research and development expenses rose to $41.2 million in Q1 2025 from $37.0 million in Q1 2024, primarily due to costs associated with Phase 2 trials for rosnilimab and Phase 1 trials for ANB033 and ANB101 [11][19] - The net loss for Q1 2025 was $39.3 million, or $1.28 per share, compared to a net loss of $43.9 million, or $1.64 per share, in the same period of 2024 [11][16][19] Portfolio Updates - Rosnilimab is in a Phase 2b trial for rheumatoid arthritis and a Phase 2 trial for ulcerative colitis, with positive results reported in a 424-patient Phase 2b RA trial [3][8][14] - ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator, are both in Phase 1 trials, with enrollment ongoing for healthy volunteers [4][5][7] - The company has a collaboration with GSK, which includes anticipated milestone payments and royalties from the sales of Jemperli [9][12][14]

每经记者 许立波 林姿辰 每经编辑 文多 4月21日，微信公众号"梅斯肿瘤新前沿"发布8篇文章，其中部分内容与恒瑞医药（SH600276）自研PD-1（程序性死亡受体1）抑制剂卡瑞利珠单抗（商品 名：艾瑞卡）有关。网友发现，这些文章标题的第一个字可组成"佰泽安无生存获益"，遂猜测其影射百济神州（SH688235）的PD-1单抗"百泽安"（通用 名：替雷利珠单抗注射液）。此事在业内引发广泛关注。4月24日，"梅斯肿瘤新前沿"发布致歉说明，称争议内容来源于合作方投放素材。 此事表面上看是一段营销层面的偶发插曲，并迅速被企业方低调处理。其背后则是PD-1单抗市场竞争愈发激烈、格局趋于固化之下，企业在存量市场中寻 求突围所映射出的深层焦虑。 青侨阳光基金经理林伟在接受《每日经济新闻》记者采访时表示，在经过行业先发厂商7~8年的跑马圈地之后，PD-(L)1单抗［PD-1单抗药物、PD-L1（程序 性死亡配体1）单抗药物的合称］市场留给后来者建立竞争优势的差异化空间已经越来越小。"我认为行业格局已定，已经进入存量博弈阶段。"林伟表示， 当前的先发企业将主导未来的潜在增长。 但林伟也表示，如果把视野放大到整个肿瘤免疫层面， ...